Minocycline is a second-generation tetracycline that effectively crosses the blood-brain barrier. It has remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, Huntington’s and Parkinson’s diseases. However, there is no evidence about neuroprotective effects of minocycline on AD. Alzheimer’s disease (AD) is a neurodegenerative disorder characterized neurop...

Amyloidosis consists of approximately 30 protein-folding disorders in which a specific soluble precursor protein aggregates to form the insoluble fibrils amyloid. Insulin is hypothesized localized cutaneous insulin-derived (AIns) amyloidosis. Amyloid deposition at insulin injection sites can interfere with absorption, leading poor glucose control. Despite increasing prevalence diabetes mellitus...

Background: The British Precursor Protein (BRI2) influences Amyloid Precursor Protein metabolism. Results: BRI2 lowers β-amyloid peptide levels by increasing levels of secreted insulin degrading enzyme (IDE) in both cells and mice. Conclusion: BRI2 as a receptor protein regulates IDE levels and in turn promotes βamyloid degradation. Significance: Targeting the regulation of IDE may lead to new ...

Transgenic mice over-expressing mutant human amyloid precursor protein (PDAPP mouse) develop several Alzheimer’s disease (AD)-like lesions including an age-related accumulation of amyloid-?-containing neuritic plaques. Although aged, heterozygous PDAPP mice also exhibit synaptic and glial cell changes, that is characteristic of AD pathology, no evidence of neurodegeneration has been observed. T...

Abbreviations: Aβ: Amyloid-β peptide; AD: Alzheimer Disease; ALS: Amyloid Lateral Sclerosis; APP: Amyloid Precursor Protein; (BBB): Blood-Brain Barrier; DA: Dopaminergic neurons; FGF: Fibroblasts Growth Factor; HD: Huntington Disease; L-DOPA: Laevo3,4 dihydroxyphenylalanine; MAPK: Mitogen Activated Protein Kinase; MS-818: 2-piperadino-6-methyl-5-oxo-5, 6-dihydro (7H) pyrrolo [2,3d] pyrimidine m...